Antibiotics for treatment and prevention ofexacerbations of chronic obstructive pulmonary disease

Robert Wilson, Sanjay Sethi, Antonio R Anzueto, Marc Miravitlles

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Acute exacerbations (AE) can be recurrent problems for patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) increasing morbidity and mortality. Evidence suggests that ≥50% of acute exacerbations involve bacteria requiring treatment with an antibiotic which should have high activity against the causative pathogens. However, sputum analysis is not a pre-requisite for antibiotic prescription in outpatients as results are delayed and patients are likely to be colonised with bacteria in the stable state. Clinicians rely on the clinical symptoms, sputum appearance and the patient's medical history to decide if an AE-COPD should be treated with antibiotics. This article reviews the available data of antibiotic trials in AE-COPD. Management of frequent exacerbators is particularly challenging for physicians. This may include antibiotic prophylaxis, especially macrolides because of anti-inflammatory properties; though successful in reducing exacerbations, concerns about resistance development remain. Inhalation of antibiotics achieves high local concentrations and minimal systemic exposure; therefore, it may represent an attractive alternative for antibiotic prophylaxis in certain COPD patients. Inhaled antibiotic prophylaxis has been successfully used in other respiratory conditions such as non-cystic fibrosis bronchiectasis which itself might be present in COPD patients who have chronic bacterial infection, particularly with Pseudomonas aeruginosa.

Original languageEnglish (US)
Pages (from-to)497-515
Number of pages19
JournalJournal of Infection
Volume67
Issue number6
DOIs
StatePublished - Dec 2013

Fingerprint

Chronic Obstructive Pulmonary Disease
Antibiotic Prophylaxis
Anti-Bacterial Agents
Sputum
Bacteria
Therapeutics
Bronchiectasis
Macrolides
Bacterial Infections
Pseudomonas aeruginosa
Inhalation
Prescriptions
Fibrosis
Anti-Inflammatory Agents
Outpatients
Morbidity
Physicians
Mortality

Keywords

  • Acute bacterial exacerbation of COPD
  • Antibiotics
  • Chronic inflammation
  • Fluoroquinolones
  • Inhalation therapy
  • Long-term outcome
  • Macrolides

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Antibiotics for treatment and prevention ofexacerbations of chronic obstructive pulmonary disease. / Wilson, Robert; Sethi, Sanjay; Anzueto, Antonio R; Miravitlles, Marc.

In: Journal of Infection, Vol. 67, No. 6, 12.2013, p. 497-515.

Research output: Contribution to journalArticle

Wilson, Robert ; Sethi, Sanjay ; Anzueto, Antonio R ; Miravitlles, Marc. / Antibiotics for treatment and prevention ofexacerbations of chronic obstructive pulmonary disease. In: Journal of Infection. 2013 ; Vol. 67, No. 6. pp. 497-515.
@article{316b2b2a43484dd1a54ebe8e4aeb7971,
title = "Antibiotics for treatment and prevention ofexacerbations of chronic obstructive pulmonary disease",
abstract = "Acute exacerbations (AE) can be recurrent problems for patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) increasing morbidity and mortality. Evidence suggests that ≥50{\%} of acute exacerbations involve bacteria requiring treatment with an antibiotic which should have high activity against the causative pathogens. However, sputum analysis is not a pre-requisite for antibiotic prescription in outpatients as results are delayed and patients are likely to be colonised with bacteria in the stable state. Clinicians rely on the clinical symptoms, sputum appearance and the patient's medical history to decide if an AE-COPD should be treated with antibiotics. This article reviews the available data of antibiotic trials in AE-COPD. Management of frequent exacerbators is particularly challenging for physicians. This may include antibiotic prophylaxis, especially macrolides because of anti-inflammatory properties; though successful in reducing exacerbations, concerns about resistance development remain. Inhalation of antibiotics achieves high local concentrations and minimal systemic exposure; therefore, it may represent an attractive alternative for antibiotic prophylaxis in certain COPD patients. Inhaled antibiotic prophylaxis has been successfully used in other respiratory conditions such as non-cystic fibrosis bronchiectasis which itself might be present in COPD patients who have chronic bacterial infection, particularly with Pseudomonas aeruginosa.",
keywords = "Acute bacterial exacerbation of COPD, Antibiotics, Chronic inflammation, Fluoroquinolones, Inhalation therapy, Long-term outcome, Macrolides",
author = "Robert Wilson and Sanjay Sethi and Anzueto, {Antonio R} and Marc Miravitlles",
year = "2013",
month = "12",
doi = "10.1016/j.jinf.2013.08.010",
language = "English (US)",
volume = "67",
pages = "497--515",
journal = "Journal of Infection",
issn = "0163-4453",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Antibiotics for treatment and prevention ofexacerbations of chronic obstructive pulmonary disease

AU - Wilson, Robert

AU - Sethi, Sanjay

AU - Anzueto, Antonio R

AU - Miravitlles, Marc

PY - 2013/12

Y1 - 2013/12

N2 - Acute exacerbations (AE) can be recurrent problems for patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) increasing morbidity and mortality. Evidence suggests that ≥50% of acute exacerbations involve bacteria requiring treatment with an antibiotic which should have high activity against the causative pathogens. However, sputum analysis is not a pre-requisite for antibiotic prescription in outpatients as results are delayed and patients are likely to be colonised with bacteria in the stable state. Clinicians rely on the clinical symptoms, sputum appearance and the patient's medical history to decide if an AE-COPD should be treated with antibiotics. This article reviews the available data of antibiotic trials in AE-COPD. Management of frequent exacerbators is particularly challenging for physicians. This may include antibiotic prophylaxis, especially macrolides because of anti-inflammatory properties; though successful in reducing exacerbations, concerns about resistance development remain. Inhalation of antibiotics achieves high local concentrations and minimal systemic exposure; therefore, it may represent an attractive alternative for antibiotic prophylaxis in certain COPD patients. Inhaled antibiotic prophylaxis has been successfully used in other respiratory conditions such as non-cystic fibrosis bronchiectasis which itself might be present in COPD patients who have chronic bacterial infection, particularly with Pseudomonas aeruginosa.

AB - Acute exacerbations (AE) can be recurrent problems for patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) increasing morbidity and mortality. Evidence suggests that ≥50% of acute exacerbations involve bacteria requiring treatment with an antibiotic which should have high activity against the causative pathogens. However, sputum analysis is not a pre-requisite for antibiotic prescription in outpatients as results are delayed and patients are likely to be colonised with bacteria in the stable state. Clinicians rely on the clinical symptoms, sputum appearance and the patient's medical history to decide if an AE-COPD should be treated with antibiotics. This article reviews the available data of antibiotic trials in AE-COPD. Management of frequent exacerbators is particularly challenging for physicians. This may include antibiotic prophylaxis, especially macrolides because of anti-inflammatory properties; though successful in reducing exacerbations, concerns about resistance development remain. Inhalation of antibiotics achieves high local concentrations and minimal systemic exposure; therefore, it may represent an attractive alternative for antibiotic prophylaxis in certain COPD patients. Inhaled antibiotic prophylaxis has been successfully used in other respiratory conditions such as non-cystic fibrosis bronchiectasis which itself might be present in COPD patients who have chronic bacterial infection, particularly with Pseudomonas aeruginosa.

KW - Acute bacterial exacerbation of COPD

KW - Antibiotics

KW - Chronic inflammation

KW - Fluoroquinolones

KW - Inhalation therapy

KW - Long-term outcome

KW - Macrolides

UR - http://www.scopus.com/inward/record.url?scp=84887017757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887017757&partnerID=8YFLogxK

U2 - 10.1016/j.jinf.2013.08.010

DO - 10.1016/j.jinf.2013.08.010

M3 - Article

VL - 67

SP - 497

EP - 515

JO - Journal of Infection

JF - Journal of Infection

SN - 0163-4453

IS - 6

ER -